STAA

Business Context and Reporting Period

Company: STAAR Surgical Company (STAA)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended January 2, 2026 (53-week period)
Business Overview: STAAR designs, develops, and sells Implantable Collamer Lenses (ICLs) for refractive surgery. Approximately 100% of net sales are derived from ICLs. The company operates globally with significant manufacturing in the U.S. and Switzerland, and sales in over 85 countries. 91% of revenue is generated outside the United States.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 23.7% year-over-year, primarily driven by a 52% drop in sales to China distributors (from $162.3M to $77.8M). This was due to elevated distributor inventory levels from 2024 and weak consumer consumption in China.
• Profitability: The company reported a net loss of $80.4 million in 2025 compared to a net loss of $20.2 million in 2024. This deterioration was driven by lower revenue and significant one-time charges.
• One-Time Charges:
  • Merger Costs: $17.1 million incurred related to the terminated merger with Alcon.
  • Restructuring: $28.6 million in charges related to leadership realignment, workforce reduction ($12.4M), and asset impairments ($12.7M).
• Inventory Management: Finished goods inventory increased to $55.5 million (up from $43.3 million) as the company expanded manufacturing in Switzerland and built consignment inventory in China to mitigate tariff risks. However, DOH improved significantly to 219 days from 367 days.
• Merger Termination: The proposed merger with Alcon was terminated on January 6, 2026, following a shareholder vote against the deal. No termination fees were required.

Guidance, Outlook, and Risks

• Strategic Priorities for 2026: Management outlined three imperatives: "Focused Growth" (execution in key markets), "Focused Investment" (sustainable spending and surgeon education), and "Focused Innovation" (launching EVO+ in China and new lens sizes).
• China Outlook: Management expects macroeconomic conditions in China to continue impacting demand in 2026. The company is normalizing distributor inventory levels and reducing consignment inventory.
• Manufacturing Expansion: The company is ramping up production in Nidau, Switzerland. Management notes that operating two manufacturing sites will create pressure on gross margins in the near term due to lower site utilization and higher costs.
• Leadership Changes: Following the merger termination, the CEO stepped down. Warren Foust and Deborah Andrews were appointed Interim Co-CEOs. A search for a permanent CEO is underway.
• Key Risks:
  • China Dependency: China accounted for 32% of 2025 sales. Continued economic weakness or trade tensions pose significant risks.
  • Competition: Intense competition from laser vision correction (LASIK/SMILE) and low-cost Asian phakic lens manufacturers.
  • Regulatory: Complex global regulatory environment (FDA, CE Mark, NMPA) and potential for product recalls or approval delays.
  • Supply Chain: Reliance on single-source suppliers for raw materials and potential disruptions to the principal U.S. manufacturing facility.

Investor Verification Checklist

• China Sales Recovery: Verify if distributor inventory levels in China have fully normalized and if procedure volumes are stabilizing in 2026.
• Gross Margin Trajectory: Monitor whether the dual manufacturing footprint (U.S. and Switzerland) leads to sustained margin compression or if volume growth offsets the fixed costs.
• Leadership Stability: Assess the impact of the interim Co-CEO structure and the timeline for appointing a permanent CEO on strategic execution.
• Inventory Valuation: Review future quarters for potential inventory write-downs given the 3-year shelf life of ICLs and the recent buildup of consignment stock.
• Merger Costs: Confirm the finalization of the $7.0 million reimbursement to Broadwood Partners and other stockholders as disclosed in subsequent events.